[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100265385":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":38,"responsibleParty":55,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Instituto Nacional de Cancerologia de Mexico","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sarcopenic",null,"Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)",[13],"Drug: Carboplatin",{"label":15,"type":10,"description":16,"interventionNames":17},"Non Sarcopenic","Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Carboplatin","Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.",[15,9],[25],"CARBOPLAT",[27],{"name":28,"affiliation":29,"role":30},"Oscar Arrieta, MD, MSc","Instituto Nacional de Cancerologia, Columbia","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Oscar Arrieta, MD, M Sc","CONTACT","015556280400","44001","ogar@unam.mx",[39],{"facility":40,"status":41,"city":42,"state":10,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Instituto Nacional de Cancerologia","RECRUITING","Mexico City","14080","Mexico","MX",{"type":47,"coordinates":48},"Point",[49,50],-99.12766,19.42847,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":35,"phoneExt":10,"email":10},"Oscar Arrieta",{"type":30,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Oscar Gerardo Arrieta Rodríguez","Head of the Thoracic Oncology Unit and Laboratory of Experimental Oncology","100265385","impact-of-fat-free-mass-in-the-carboplatin-calculated-dose-and-chemotherapeutic-toxicity-in-patients-with-advanced-nsclc-100265385",false,"NCT02734069","Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC","Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)\n* Candidates for treatment with carboplatin plus paclitaxel 1st line\n* Performance status (ECOG 0-2)\n* Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)\n* Normal renal ultrasound prior to initiation of treatment\n\nExclusion Criteria:\n\n* Patients with renal impairment (KDOQI 3-5)\n* Patients who do not have computed tomography study at baseline\n* Uncontrolled blood pressure (\\> 140 mmHg)\n* Uncontrolled diabetes (\\> 130 mg \u002F dL)\n* Obstruction in kidney (s) or ureter (s)\n* Dehydrated patients\n* Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\\> 1 month)","ALL","18 Years",{"count":68,"type":69},132,"ESTIMATED","OBSERVATIONAL","This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin\u002FPaclitaxel in advanced NSCLC.",[73,74,75],"Lung Cancer","Sarcopenia","Toxicity",[77],"carboplatin","2025-12-17",{"date":80,"type":81},"2025-12-24","ACTUAL",{"date":83,"type":81},"2016-02",{"date":85,"type":69},"2027-12",{"name":5,"class":6},1]